Divulging the Clinical Development of LTI-03 in IPF
Time: 9:40 am
day: Day Two
Details:
- Assessing the “dual threat” of LTI-03: inhibition of the profibrotic process and lung regenerative effects
- Uncovering how biomarkers could be used to reveal these properties
